CITIZENS, INC. (CIA) stock intrinsic value fair value estimate & owner earnings analysis

Citizens, Inc. is a life insurance holding company with two businesses. The older and larger one sells U.S. dollar-denominated whole life and endowment policies to individuals living abroad, mainly in Colombia, Ecuador, Venezuela, Argentina and Taiwan, who want savings and protection that are insulated from their local currencies. The newer one is a U.S. final-expense (burial) insurance business, sold through Security Plan Life, Magnolia Guaranty and CICA Life Insurance Company of America, concentrated in Louisiana, Mississippi and Arkansas. The company has no borrowings: its $20 million bank credit line, which runs to May 2027, was undrawn at the end of 2025. How we measure earnings. We start from the cash the business actually generates from operations, remove short-term timing swings in receivables and payables, and subtract stock-based pay and the small amount spent on office and computer equipment. We deliberately leave in the insurance-specific movements in reserves, policyholder balances and commission costs of writing new policies, because for a life insurer those are the ordinary economics of collecting premiums now and paying benefits later. On that basis the business produced about $24.1 million in 2023, $16.6 million in 2024 and $17.5 million in 2025. The 2024 figure absorbed a one-time $3.5 million charge for legal fees awarded against the company in a trade-secret lawsuit. We treat that judgment separately as an amount owed, so we add it back to the year, which gives about $20.1 million. We anchor on the middle of those three years: about $20.1 million, or roughly $0.39 per share. We do not use the much larger figures of 2016 to 2022, because that cash came from a reserve pool that was still growing quickly. That pool has since stopped growing, because a large group of decades-old endowment policies is now reaching maturity. As a cross-check, reported pre-tax income was $15.0 million in 2024 and $17.5 million in 2025. Note that 2025 accounting profit was helped by about $14.9 million of favorable reserve re-measurements. Those do not affect our cash-based figure, which is one reason we rely on cash rather than reported profit. What changed recently. Matured-endowment payouts rose to a record $76 million in 2025, up $23 million, and the company's annual report says it expects them to stay elevated but slightly lower over the next few years. The first half of 2026 was weak. Premiums of $83.6 million and investment income of $34.3 million were both flat year on year, but operating cash flow fell to $1.7 million from $4.2 million, and pre-tax income fell to $1.8 million from $5.1 million. The second quarter of 2026 showed a small loss. U.S. final-expense sales have grown fast since late 2023, and the up-front commissions on those sales absorb cash today. The company has started reinsuring part of that new business to ease the strain. Internationally, Taiwan sales are down because of succession problems at the main local distributor. Venezuela, one of the largest markets, is under pressure from a strong dollar, a local dollar shortage and political instability. Colombia, Ecuador and Argentina grew in 2025. Growth check. Cash earnings grew about 5% in 2025. For 2026 we assume a fall of about 14%, to roughly $15.0 million, because two consecutive weak quarters in 2026 point that way. We credit no growth above levels the business has already reached. Total revenue has been essentially flat for a decade, between about $232 million and $256 million a year. Growth in the U.S. business has so far been offset by shrinkage abroad, and we have no signed contract or demonstrated trend showing that balance changing. Base case: 2026 is the low point, at about $15.0 million. As endowment maturities ease from their 2025 peak, as the filing indicates they will, cash earnings get back to the 2025 level of $17.5 million by 2028. They then climb gradually to the $20.1 million anchor by 2032, a level the business already reached in 2024 with its U.S. expansion already under way, and stay there. After the ten-year window we hold that level flat rather than assume growth. The reason is the company's record of selling these policies abroad since 1975, combined with a decade of flat revenue. The business is worth about $322 million. It owes no borrowings. We subtract about $4.8 million for the 2024 trade-secret lawsuit judgment, which is under appeal: about $1.3 million awarded to two former consultants plus about $3.5 million of the other side's legal fees. That leaves about $317 million, or $6.13 per share. Bear case (roughly the one-in-ten worse outcome): Taiwan distribution stays impaired, Venezuela keeps deteriorating, and endowment maturities keep outrunning new international sales. Capital strain forces the company to reinsure more of its U.S. growth. Cash earnings start at about $14.0 million in 2026 and decline about 3% to 4% a year to roughly $10.5 million by 2035. They then hold there, supported by the U.S. burial-insurance block and the stable Colombian, Ecuadorian and Argentine books. The business is worth about $188 million. It owes the lawsuit judgment plus post-judgment interest, about $5.3 million. That leaves about $183 million, or $3.54 per share. Bull case (roughly the one-in-ten better outcome): the U.S. policies sold since 2023, whose commissions are already paid, keep generating renewal premiums, and the existing reinsurance treaty limits new-business strain. At the same time, endowment maturities decline as the filing indicates. Cash earnings recover from about $16.0 million in 2026 to about $24.1 million by 2032, the level the business actually produced in 2023, and hold there. The company wins its appeal and pays nothing. The business is worth about $379 million with nothing owed, or $7.33 per share. In every case, value beyond 2035 is a large share of the total, roughly 52% to 59%. The valuation therefore depends heavily on the durability of the international franchise. We add nothing for any capital the insurance subsidiaries might hold above what regulators and policyholders require, because we could not measure a surplus that could actually be paid out. What changed since our last look. Our previous estimates were $4.36, $7.01 and $10.92 for the bear, base and bull cases. We have lowered all three. Our earlier central and upside cases assumed that fast U.S. growth would carry earnings above anything the business has produced recently. No contract or demonstrated trend supports that, and the company's flat decade of revenue argues against it, so no case now goes above a level already achieved. Two weak quarters in 2026 lower the near-term path in every case. Working the other way, we now recognize that 2024 was depressed by a one-time legal charge, which raises our starting earnings level. The company's own statement that endowment maturities peaked in 2025 also supports the recovery in our central and upside cases. We now charge the trade-secret judgment in the central case rather than only in the downside, because the judgment has been entered and the company has posted an appeal bond. The debt position is unchanged: the company has no borrowings, so nothing is subtracted for lenders in any case. Margin-of-safety price. Several things are hard to measure from the outside: a business earning well below its level of a decade ago, heavy exposure to Venezuela's and Argentina's economies, a key Taiwan distributor in difficulty, and a small company. For those reasons the estimate calls for a wide margin of safety. The margin-of-safety price is about $3.30 per share, below even our downside estimate. Two things we could not fully reconcile from the filings are why operating cash flow fell so much more than premiums in the first half of 2026, and how the lawsuit appeal will end.